UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10−Q

 

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: June 30, 2024

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to _____________

 

Commission File Number: 000-31377

 

REFLECT SCIENTIFIC, INC.
(Exact name of registrant as specified in its charter)

 

Utah   87-0642556

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

1266 South 1380 West, Orem, UT   84058
(Address of principal executive offices)   (Zip Code)

 

(801) 226-4100
(Registrant’s telephone number, including area code)

 

N/A
(Former name, former address and formal fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

1 

 

 

Large accelerated filer   Accelerated filer
Non-accelerated filer   Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 

Yes No

 

As of August 12, 2024, there were 85,664,086 common shares of the registrant issued and outstanding.

 

2 

 

REFLECT SCIENTIFIC, INC.

 

Quarterly Report on Form 10-Q

Period Ended June 30, 2024

 

 

TABLE OF CONTENTS

 

PART I

FINANCIAL INFORMATION

 

Item 1: Financial Statements 4
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations 12
Item 3: Quantitative and Qualitative Disclosure about Market Risk 16
Item 4: Controls and Procedures 17

 

PART II

OTHER INFORMATION

 

Item 1: Legal Proceedings 17
Item 1A. Risk Factors 17
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 17
Item 3: Defaults Upon Senior Securities 17
Item 4: Mine Safety Disclosure 17
Item 5: Other Information 17
Item 6: Exhibits 18

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3 

 

PART I

FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS.

 

 

REFLECT SCIENTIFIC, INC.

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

 

    Page
Condensed Consolidated Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023   5
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2024 and 2023 (Unaudited)   6
Condensed Consolidated Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2024 and 2023 (Unaudited)   7
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 (Unaudited)   8
Notes to Condensed Consolidated Financial Statements (Unaudited)   9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4 

 

REFLECT SCIENTIFIC, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   

June 30,

2024

    December 31, 2023  
ASSETS   (Unaudited)        
             
Current Assets            
Cash and cash equivalents   $ 1,102,696     $ 1,277,951  
Accounts receivable, net     110,592       108,191  
Inventories, net     835,667       972,293  
Prepaid expenses and other current assets     14,550       11,715  
Total Current Assets     2,063,505       2,370,150  
                 
Operating lease right-of-use assets     200,026       235,653  
Goodwill     60,000       60,000  
Other long-term assets     3,100       3,100  
TOTAL ASSETS   $ 2,326,631     $ 2,668,903  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY                
                 
Current Liabilities                
Accounts payable and accrued expenses   $ 52,904     $ 86,241  
Customer deposits     90,369       447,444  
Current portion of operating lease liabilities     72,802       62,681  
Total Current Liabilities     216,075       596,366  
                 
Operating lease liabilities, net of current portion     140,966       179,963  
TOTAL LIABILITIES     357,041       776,329  
                 
Stockholders' Equity                
Preferred Stock, $0.01 par value, 5,000,000 shares authorized; none issued and outstanding as of June 30, 2024 and December 31, 2023     -       -  
Common stock, $0.01 par value, 100,000,000 shares authorized; 85,664,086 shares issued and outstanding as of June 30, 2024 and December 31, 2023     856,640       856,640  
Additional paid-in capital     20,302,681       20,302,681  
Accumulated deficit     (19,189,731 )     (19,266,747 )
TOTAL STOCKHOLDERS’ EQUITY     1,969,590       1,892,574  
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 2,326,631     $ 2,668,903  

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5 

 

REFLECT SCIENTIFIC, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

 

   

Three Months Ended

June 30,

   

Six Months Ended

June 30,

 
    2024     2023     2024     2023  
Revenues   $ 590,071     $ 124,384     $ 1,018,826     $ 365,511  
Cost of goods sold     231,514       63,850       418,480       177,483  
Gross profit     358,557       60,534       600,346       188,028  
                                 
Operating Expenses                                
Salaries and wages     148,054       154,569       290,668       316,844  
General and administrative     107,555       81,361       239,859       188,353  
Research and development     4,605       5,380       11,980       11,446  
Total Operating Expenses     260,214       241,310       542,507       516,643  
                                 
INCOME (LOSS) FROM OPERATIONS     98,343     (180,776 )     57,839       (328,615 )
                                 
Other Income (Expense)     10,644       (312  )     19,177        (312  ) 
                                 
NET INCOME (LOSS) BEFORE INCOME TAXES     98,343     (180,776 )     57,839       (328,615 )
INCOME TAX EXPENSE    
-
   
-
     
-
     
-
 
NET INCOME (LOSS)   $ 108,987   $ (181,088 )   $ 77,016     $ (328,927 )
                                 
Income (loss) per common share                                
Basic and diluted   $ 0.00   $ (0.00 )   $ 0.00     $ (0.00 )
                                 
Weighted average shares outstanding                                
Basic and diluted     85,664,086       85,214,086       85,664,086       85,214,086  
                                   

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6 

 

REFLECT SCIENTIFIC, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

 

 

Three and Six Months Ended June 30, 2024

 

    Common Shares    

Additional

Paid-In

    Accumulated    

Total

Stockholders’

 
    Shares     Amount     Capital     Deficit     Equity  
Balance at December 31, 2023     85,664,086     $ 856,640     $ 20,302,681     $ (19,266,747 )   $ 1,892,574  
Net loss     -       -       -       (31,971 )     (31,971 )
Balance at March 31, 2024     85,664,086     $ 856,640     $ 20,302,681     $ (19,298,718 )   $ 1,860,603  
Net income     -       -       -       108,987       108,987  
Balance at June 30, 2024     85,664,086     $ 856,640     $ 20,302,681     $ (19,189,731 )   $ 1,969,590  
                                         

 

Three and Six Months Ended June 30, 2023

 

    Common Shares    

Additional

Paid-In

    Accumulated    

Total

Stockholders’

 
    Shares     Amount     Capital     Deficit     Equity  
Balance at December 31, 2022     85,214,086     $ 852,140     $ 20,252,181     $ (18,807,719 )   $ 2,296,602  
Stock-based compensation     -       -       6,875       -       6,875  
Net loss     -       -       -       (147,839 )     (147,839 )
Balance at March 31, 2023     85,214,086     $ 852,140     $ 20,259,056     $ (18,955,558 )   $ 2,155,638  
Stock-based compensation     -       -       6,875       -       6,875  
Net loss     -       -       -       (181,088 )     (181,088 )
Balance at June 30, 2023     85,214,086     $ 852,140     $ 20,265,931     $ (19,136,646 )   $ 1,981,425  

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

7 

 

REFLECT SCIENTIFIC, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   

For the Six Months Ended

June 30,

 
    2024     2023  
CASH FLOWS FROM OPERATING ACTIVITIES                
Net income (loss)   $ 77,016     $ (328,927 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Stock-based compensation     -       13,750  
Amortization of right-of-use assets     35,627       29,257  
Changes in operating assets and liabilities:                
Accounts receivable     (2,401 )     36,612  
Inventories     136,626       (79,734 )
Prepaid expenses and other current assets     (2,835 )     (3,703 )
Accounts payable and accrued expenses     (33,338 )     (35,398 )
Customer deposits     (357,075 )     425,607  
Operating lease liabilities     (28,876 )     (30,633 )
Net cash (used in) provided by operating activities     (175,255 )     26,831  
                 
CASH FLOWS FROM INVESTING ACTIVITIES                
Net cash provided by investing activities     -       -  
                 
CASH FLOWS FROM FINANCING ACTIVITIES                
Net cash provided by financing activities     -       -  
                 
NET CHANGE IN CASH AND CASH EQUIVALENTS     (175,255 )     26,831  
                 
CASH AND CASH EQUIVALENTS                
Beginning of the period     1,277,951       1,381,927  
End of the period   $ 1,102,696     $ 1,408,758  
                 
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION                
Cash paid for interest   $
-
    $ -  
Cash paid for income taxes   $
-
    $ -  

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

8 

 

REFLECT SCIENTIFIC, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

NOTE 1—BASIS OF PRESENTATION AND OTHER INFORMATION

 

The accompanying unaudited condensed consolidated financial statements of Reflect Scientific, Inc. (the “Company,” “we,” “us,” or “our”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q of Regulation S-X. They do not include all the information and footnotes required by GAAP for complete financial statements. The December 31, 2023 consolidated balance sheet data was derived from audited financial statements but do not include all disclosures required by GAAP. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 29, 2024. The interim unaudited condensed consolidated financial statements should be read in conjunction with those consolidated financial statements included in the Form 10-K. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.

 

Recently Issued Accounting Pronouncements

 

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about reportable segment’s profit or loss and assets that are currently required annually. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. These amendments are to be applied retrospectively. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements.

 

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which enhances the transparency and decision usefulness of income tax disclosures by requiring; (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. These amendments are to be applied prospectively, with retrospective application permitted. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements.

 

The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to our condensed consolidated financial statements.

 

NOTE 2—DISAGGREGATION OF REVENUES

 

Our revenue is disaggregated based on product category and geographical region. We recognize revenue from the sale of scientific equipment for the life sciences and manufacturing industries. Our products include non-mechanical Cyrometrix freezers, chillers, and original equipment manufacturer (“OEM”) value-added products and components for the life sciences industry.

 

9 

 

 

The Company’s revenues for the three months ended June 30, 2024 and 2023 are disaggregated as follows:

 

    For the Three Months Ended June 30, 2024  
    United States     International     Total  
Revenues                        
     Freezers and chillers   $ 391,198     $ -     $ 391,198  
     OEM and other     159,385       39,488       198,873  
Total Revenues $ 550,583     $ 39,488     $ 590,071  

 

    For the Three Months Ended June 30, 2023  
    United States     International     Total  
Revenues                        
    Freezers and chillers   $ 10,508     $ -     $ 10,508  
    OEM and other     81,155       32,721       113,876  
Total Revenues   $ 91,663     $ 32,721     $ 124,384  

 

The Company’s revenues for the six months ended June 30, 2024 and 2023 are disaggregated as follows:

 

    Six Months Ended June 30, 2024
    United States     International     Total  
    Revenues                  
    Freezers and chillers   $ 655,468     $ -     $ 655,468  
    OEM and other     297,181       66,177       363,358  
   Total Revenues   $ 952,649     $ 66,177     $ 1,018,826  

 

    Six Months Ended June 30, 2023
    United States     International     Total  
    Revenues                  
    Freezers and chillers   $ 55,758     $ -     $ 55,758  
    OEM and other     209,035       100,718       309,753  
    Total Revenues   $ 264,793     $ 100,718     $ 365,511  

 

NOTE 3—INVENTORIES

 

Inventories at June 30, 2024 and December 31, 2023 consisted of the following:

 

    June 30,     December 31,  
    2024     2023  
Finished goods   $ 184,808     $ 493,565  
Raw materials     756,903       584,772  
Total inventories     941,711       1,078,337  
Less reserve for obsolescence     (106,044 )     (106,044 )
Total inventories, net   $ 835,667     $ 972,293  

 

Inventory balances are composed of finished goods and raw materials. Work in process inventory is immaterial to the condensed consolidated financial statements.

 

10 

 

 

NOTE 4—LEASES

 

The following was included in our condensed consolidated balance sheets at June 30, 2024 and December 31, 2023:

 

    June 30,   December 31,  
    2024   2023  
Operating lease right-of-use assets   $ 200,026   $ 235,653  
               
Lease liabilities, current portion     72,802     62,681  
Lease liabilities, long-term     140,966     179,963  
Total operating lease liabilities   $ 213,768   $ 242,644  
               
Weighted-average remaining lease term (months)     29     35  
Weighted average discount rate     10.5 %   10.5 %

 

Total lease expense for the three and six months ended June 30, 2024 and 2023 is as follows:

 

   

Three Months Ended

June 30,

   

Six Months Ended

June 30,

 
    2024     2023     2024     2023  
Operating lease expense   $ 23,875     $ 15,216     $ 47,750     $ 30,432  
Variable lease expense     -       7,202       -       11,639  
Total lease expense   $ 23,875     $ 22,418     $ 47,750     $ 42,071  

 

Cash payments included in the measurement of our operating lease liabilities were $20,777 and $15,977 for the three months ended and $41,002 and $31,808 for the six months ended June 30, 2024 and 2023, respectively.

 

As of June 30, 2024, maturities of operating lease liabilities were as follows:

  

Year Ending December 31,   Amount  
2024   $ 44,307  
2025     98,532  
2026     101,708  
Total     244,547  
Less: imputed interest     (30,779 )
Total operating lease liabilities   $ 213,768  

 

NOTE 5—STOCKHOLDERS’ EQUITY

 

Common Stock

 

As of June 30, 2024 and December 31, 2023, the Company was authorized to issue 100,000,000 common shares, of which 85,664,086 common shares were issued and outstanding.

 

11 

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

The following management’s discussion and analysis of financial condition and results of operations provides information that management believes is relevant to an assessment and understanding of our plans and financial condition. The following financial information is derived from our financial statements and should be read in conjunction with such financial statements and notes thereto set forth elsewhere herein.

 

Use of Terms

 

Except as otherwise indicated by the context and for the purposes of this report only, references in this report to “we,” “us,” “our” and the “Company” refer to Reflect Scientific, Inc., and its consolidated subsidiaries.

 

Special Note Regarding Forward Looking Statements

 

This report contains forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

 

  Changes in Company-wide strategies, which may result in changes in the types or mix of businesses in which our Company is involved or chooses to invest;

 

  Changes in U.S., global or regional economic conditions;

 

  Changes in U.S. and global financial and equity markets, including significant interest rate fluctuations, which may impede our Company’s access to, or increase the cost of, external financing for our operations and investments;

 

  Increased competitive pressures, both domestically and internationally;

 

  Legal and regulatory developments, such as regulatory actions affecting environmental activities;

 

  The imposition by foreign countries of trade restrictions and changes in international tax laws or currency controls;

 

  Adverse weather conditions or natural disasters, such as hurricanes and earthquakes, labor disputes, which may lead to increased costs or disruption of operations.

 

In some cases, you can identify forward-looking statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results.

 

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

12 

 

 

The forward-looking statements made in this report relate only to events or information as of the date on which the statements are made in this report. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

 

Overview

 

Reflect Scientific is engaged in the manufacture and distribution of innovative products targeted at the life science market. Our customers include hospitals, diagnostic laboratories, pharmaceutical and biotech companies, cold chain management, universities, government and private sector research facilities, chemical and industrial companies.

 

Our goal is to provide our customers with the best solution for their needs. This philosophy extends into our business strategies and acquisition plans. Through a series of strategic acquisitions, we acquired technology that has enabled us to expand our line of products to align with, and capitalize on, market needs. Our growing product portfolio includes ultra-low temperature freezers, blast freezers, solvent chillers and refrigerated transportation in addition to supplying OEM products to the life sciences industry.

 

Our Cryometrix brand ultra-low temperature and blast freezers innovative design enables our customers to save substantially on energy costs related to cryogenic storage. Ultra-low temperature freezers are used worldwide for the storage of vaccines, DNA, RNA, proteins and many other biological and chemical substances. There is a growing need for energy efficient, reliable ultra-low temperature storage units. Our Cryometrix freezers are targeted to this growing market and we have had tremendous success in blood storage and pharmaceutical manufacturing applications. The application of this technology for use in refrigerated trailers (commonly called “reefers”) used to transport goods which need to be maintained in a cold environment significantly broadens the market for this technology. The utilization of this technology in reefers eliminates the current method of cooling, which uses engines run on hydrocarbon fuels. The Cryometrix technology is pollutant free and is more efficient and cost effective than the technologies currently used. Reflect Scientific has added a new product line of solvent chillers. Solvent chillers are used in natural products extraction for optimizing product yield and purity.

 

Recent Developments

 

None.

 

Critical Accounting Policies and Estimates

 

The preparation of the unaudited condensed consolidated financial statements requires our management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On a regular basis, we evaluate these estimates. These estimates are based on management’s historical industry experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.

 

For a description of the accounting policies that, in management’s opinion, involve the most significant application of judgment or involve complex estimation and which could, if different judgment or estimates were made, materially affect our reported financial position, results of operations, or cash flows, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 29, 2024.

 

During the three months and six months ended June 30, 2024, there were no significant changes in our accounting policies and estimates.

 

13 

 

 

Results of Operations

 

Comparison of the Three Months Ended June 30, 2024 and 2023

 

The following table sets forth key components of our results of operations during the three months ended June 30, 2024 and 2023:

 

    For the Three Months Ended June 30,  
    2024     2023  
    Amount     % of Revenues     Amount     % of Revenues  
Revenues   $ 590,071       100.0 %   $ 124,384       100.0 %
Cost of goods sold     231,514       39.2 %     63,850       51.3 %
Gross profit     358,557       60.8 %     60,534       48.7 %
                                 
Operating Expenses                                
Salaries and wages     148,054       25.1 %     154,569       124.3 %
General and administrative     107,555       18.2 %     81,361       65.4 %
Research and development     4,605       0.8 %     5,380       4.3 %
Total Operating Expenses     260,214       44.1 %     241,310       194 %
                                 
Income (loss) from operations     98,343       16.7 %     (180,776 )     (145.3) %
                                 
Other income     10,644       1.8 %     -       -  
                                 
Net loss before income taxes     108,987       18.5 %     (180,776 )     (145.3) %
Income tax expense     -       -       312       0.3 %
Net income (loss)   $ 108,987       18.5 %   $ (181,088 )     (145.6) %

 

Revenues. Revenues increased by $465,687, or 374.4%, to $590,071 for the three months ended June 30, 2024, as compared to $124,384 for the three months ended June 30, 2023. Such increase was primarily due to a heightened demand for freezer and chiller sales, driven by increased customer capital expenditures during the current period.

 

Cost of goods sold. Cost of goods sold increased by $167,664, or 263%, to $231,514 for the three months ended June 30, 2024, as compared to $63,850 for the three months ended June 30, 2023. Such increase was primarily due to increased freezer and chillers sales during the current period.

 

Gross profit. Our gross profit as a percentage of sales increased to 60.8% for the three months ended June 30, 2024, as compared to 48.7% for the three months ended June 30, 2023. The increase in gross profit percentage was primarily due to the increase in freezer and chiller sales during the current period, which have better margins than other products. This was partially offset by increased product costs during the current period.

 

Salaries and wages. Salaries and wages decreased by $6,515, or 4.2%, to $148,054 for the three months ended June 30, 2024, as compared to $154,569 for the three months ended June 30, 2023. Such decrease was primarily due to no stock-based compensation during the current period and decreased employee headcount.

 

General and administrative. General and administrative expenses increased by $26,194 or 32.2%, to $107,555 for the three months ended June 30, 2024, as compared to $81,361 for the three months ended June 30, 2023. Such increase was primarily due to increased advertising and marketing, professional fees, public filing costs, and rent expense during the current period.

 

Research and development. Research and development expenses decreased by $775, or 14.4%, to $4,605 for the three months ended June 30, 2024, as compared to $5,380 for the three months ended June 30, 2023. Such decrease was primarily a result of resource allocation to marketing and production.

 

14 

 

Other income. Other income was $10,644 for the three months ended June 30, 2024, as compared to $0 for the three months ended June 30, 2023. The increase in the current period was from interest income earned on our business money market savings accounts, which were opened during the fourth quarter of 2023.

 

Net income. As a result of the cumulative effect of the factors described above, our net income was $108,987 for the three months ended June 30, 2024, as compared to a net loss of $181,088 for the three months ended June 30, 2023. Management continues to look for opportunities to increase sales, improve gross margins and control ongoing operating expenses.

 

Comparison of the Six Months Ended June 30, 2024 and 2023

 

The following table sets forth key components of our results of operations during the six months ended June 30, 2024 and 2023, both in dollars and as a percentage of our revenues.

 

    Six Months Ended June 30,  
    2024     2023  
    Amount    

% of

Revenues

    Amount    

% of

Revenues

 
Revenues   $ 1,018,826       100 %   $ 365,511       100 %
Cost of goods sold     418,480       41.1 %     177,483       48.6 %
Gross profit     600,346       58.9 %     188,028       51.4 %
                                 
Operating expenses                                
Salaries and wages     290,668       28.5 %     316,844       86.7 %
General and administrative     239,859       23.5 %     188,353       51.5 %
Research and development     11,980       1.2 %     11,446       3.1 %
Total operating expenses     542,507       53.2     516,643       141.3
                                 
Income (loss) from operations     57,839       5.7 %     (328,615)       (89.9) %
                                 
Other Income     19,177       1.9 %     -       - %
                                 
Income tax expense     -       - %     (312)       (0.1) %
                                 
Net income (loss)   $ 77,016       7.6 %   $ (328,927)       (90.0) %

 

Revenues. Revenues increased by $653,315, or 178.7%, to $1,018,826 for the six months ended June 30, 2024, from $365,511 for the six months ended June 30, 2023. Such increase was primarily due to a significant increase in freezer and chiller sales.

 

Cost of goods sold. Cost of goods sold increased by $240,997 or 135.8%, to $418,480 for the six months ended June 30, 2024, from $177,483 for the six months ended June 30, 2023. Such increase was primarily due to increased freezer and chillers sales, as well as increased production costs.

 

Gross profit. Our gross profit as a percentage of sales increased to 58.9% for the six months ended June 30, 2024, compared to 51.4% for the six months ended June 30, 2023. The increase in gross profit percentage was primarily due to the increase in freezer and chiller sales, which have better margins than other products

 

Salaries and wages. Salaries and wages decreased by $26,176, or 8.3%, to $290,668 for the six months ended June 30, 2024, from $316,844 for the six months ended June 30, 2023. Such decrease was primarily due to decreased headcount.

 

15 

 

General and administrative. General and administrative expenses increased by $51,506, or 27.3%, to $239,859 for the six months ended June 30, 2024, from $188,353 for the six months ended June 30, 2023. Such increase was primarily due to the increased in public filing and insurance costs.

 

Research and development. Research and development expenses increased by $534, or 4.7%, to $11,980 for the six months ended June 30, 2024, from $11,446 for the six months ended June 30, 2023. Such increase was primarily a result of increased costs.

 

Net income (loss). As a result of the cumulative effect of the factors described above, our net income was $77,016 for the six months ended June 30, 2024, as compared to net loss of $328,927 for the six months ended June 30, 2023. Management has looked for opportunities to increase sales, improve gross margins and control ongoing operating expenses.

 

Liquidity and Capital Resources

 

As of June 30, 2024 and December 31, 2023, our current assets exceeded current liabilities by $1,847,430 and $1,773,784, respectively, and we had cash and cash equivalents of $1,102,696 and $1,277,951, respectively. To date, we have financed our operations primarily through revenue generated from operations, cash proceeds from financing activities, borrowings, and equity contributions by our shareholders.

 

Summary of Cash Flow

 

The following table provides detailed information about our net cash flow for the period indicated:

 

   

Six Months Ended

June 30,

 
    2024     2023  
Net cash (used in) provided by operating activities   $ (175,255 )     26,831  
Net cash provided by investing activities     -       -  
Net cash provided by financing activities     -       -  
Net change in cash and cash equivalents     (175,255 )     26,831  
                 
Cash and cash equivalents at beginning of period     1,277,951       1,381,927  
Cash and cash equivalents at end of period   $ 1,102,696     $ 1,408,758  

 

Net cash used in operating activities was $175,255 and provided by operating activities $26,831 for the six months ended June 30, 2024 and 2023, respectively. Significant factors affecting operating cash flows were primarily a result of increased accounts receivable during the current period.

 

We continue working to enhance our on-line ordering system to increase sales, develop the market for our ultra-low temperature freezers, work with current vendors to obtain more favorable pricing, and locate new vendors to provide opportunities to further reduce our cost of goods.

 

We will continue to focus our efforts on our core business activities while pursuing capital resources and evaluating potential future acquisitions which fit within and enhance our core business.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not applicable.

16 

 

 

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to our management, including our chief executive officer and chief principal officer, as appropriate, to allow timely decisions regarding required disclosure.

 

As required by Rule 13a-15(e) of the Exchange Act, our management has carried out an evaluation, with the participation and under the supervision of our chief executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as of June 30, 2024. Based upon, and as of the date of this evaluation, our chief executive officer and principal financial officer determined that there have been no changes in our internal controls over financial reporting as of June 30, 2024 to the material weaknesses described in Item 9A “Controls and Procedures” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, our disclosure controls and procedures were not effective.

 

PART II

OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these, or other matters, may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

 

ITEM 1A. RISK FACTORS.

 

Not applicable.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

During the quarter ended June 30, 2024, none of the Company’s directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408 of Regulation S-K.

 

17 

 

 

ITEM 6. Exhibits

 

(a)Exhibits.

 

Exhibit No. Title of Document

Location if other than attached hereto

 

3.1 Articles of Incorporation 10-SB Registration Statement*
3.2 Articles of Amendment to Articles of Incorporation 10-SB Registration Statement*
3.3 By-Laws 10-SB Registration Statement*
3.4 Articles of Amendment to Articles of Incorporation 8-K Current Report dated December 31, 2003*
3.5 Articles of Amendment to Articles of Incorporation 8-K Current Report dated December 31, 2003*
3.6 Articles of Amendment September 30, 2004 10-QSB Quarterly Report*
3.7 By-Laws Amendment September 30, 2004 10-QSB Quarterly Report*
4.1 Debenture 8-K Current Report dated June 29, 2008*
4.2 Form of Purchasers Warrant 8-K Current Report dated June 29, 2008*
4.3 Registration Rights Agreement 8-K Current Report dated June 29, 2008*
4.4 Form of Placement Agreement 8-K Current Report dated June 29, 2008*
10.1 Securities Purchase Agreement 8-K Current Report dated June 29, 2008*
10.2 Placement Agent Agreement 8-K Current Report dated June 29, 2008*
10.3 JMST Purchase Agreement 8-K Current Report dated April 4, 2006*
10.4 Cryomastor Merger Agreement 8-K Current Report dated April 19, 2006*
10.5 Image Labs Merger Agreement 8-K Current Report dated November 15, 2006*
10.7 Debenture Settlement 8-K Current Report dated November 17, 2006*
14 Code of Ethics December 31, 2003 10-K Annual Report*
21 Subsidiaries of the Company December 31, 2006 10-K Annual Report*

 

Exhibit No. Title of Document Location if other than attached hereto
31.1 302 Certification of Kim Boyce This Filing
31.2 302 Certification of Kim Boyce This Filing
32 906 Certification This Filing

 

Exhibits

 

Additional Exhibits Incorporated by Reference

* Reflect California Reorganization 8-K Current Report dated December 31, 2003
* JMST Acquisition 8-K Current Report dated April 4, 2006
* Cryomastor Reorganization 8-K Current Report dated September 27, 2006
* Image Labs Merger Agreement Signing 8-K Current Report dated November 15, 2006
* All Temp Merger Agreement Signing 8-K Current Report dated November 17, 2006
* All Temp Merger Agreement Closing 8-KA Current Report dated November 17, 2006
* Image Labs Merger Agreement Closing 8-KA Current Report dated November 15, 2006
* Debenture Placement 8-K Current Report dated June 29, 2007

 

* Previously filed and incorporated by reference.

18 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Reflect Scientific, Inc.

(Registrant)

 

 

Date: August 13, 2024                                                                By: /s/ Kim Boyce

Kim Boyce, Chief Executive Officer and Director

 

Date: August 13, 2024                                                                 By: /s/ Kim Boyce

Kim Boyce, Principal Financial Officer

19 

 

10-Q 0.00 0.00 0.00 0.00 85214086 85214086 85664086 85664086 false --12-31 Q2 0001103090 0001103090 2024-01-01 2024-06-30 0001103090 2024-08-12 0001103090 2024-06-30 0001103090 2023-12-31 0001103090 2024-04-01 2024-06-30 0001103090 2023-04-01 2023-06-30 0001103090 2023-01-01 2023-06-30 0001103090 us-gaap:CommonStockMember 2023-12-31 0001103090 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001103090 us-gaap:RetainedEarningsMember 2023-12-31 0001103090 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001103090 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001103090 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001103090 2024-01-01 2024-03-31 0001103090 us-gaap:CommonStockMember 2024-03-31 0001103090 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001103090 us-gaap:RetainedEarningsMember 2024-03-31 0001103090 2024-03-31 0001103090 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001103090 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001103090 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001103090 us-gaap:CommonStockMember 2024-06-30 0001103090 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001103090 us-gaap:RetainedEarningsMember 2024-06-30 0001103090 us-gaap:CommonStockMember 2022-12-31 0001103090 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001103090 us-gaap:RetainedEarningsMember 2022-12-31 0001103090 2022-12-31 0001103090 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001103090 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001103090 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001103090 2023-01-01 2023-03-31 0001103090 us-gaap:CommonStockMember 2023-03-31 0001103090 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001103090 us-gaap:RetainedEarningsMember 2023-03-31 0001103090 2023-03-31 0001103090 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001103090 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001103090 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001103090 us-gaap:CommonStockMember 2023-06-30 0001103090 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001103090 us-gaap:RetainedEarningsMember 2023-06-30 0001103090 2023-06-30 0001103090 rscf:FreezersAndChillersMember country:US 2024-04-01 2024-06-30 0001103090 rscf:FreezersAndChillersMember rscf:InternationalMember 2024-04-01 2024-06-30 0001103090 rscf:FreezersAndChillersMember 2024-04-01 2024-06-30 0001103090 rscf:OEMAndOtherMember country:US 2024-04-01 2024-06-30 0001103090 rscf:OEMAndOtherMember rscf:InternationalMember 2024-04-01 2024-06-30 0001103090 rscf:OEMAndOtherMember 2024-04-01 2024-06-30 0001103090 country:US 2024-04-01 2024-06-30 0001103090 rscf:InternationalMember 2024-04-01 2024-06-30 0001103090 rscf:FreezersAndChillersMember country:US 2023-04-01 2023-06-30 0001103090 rscf:FreezersAndChillersMember rscf:InternationalMember 2023-04-01 2023-06-30 0001103090 rscf:FreezersAndChillersMember 2023-04-01 2023-06-30 0001103090 rscf:OEMAndOtherMember country:US 2023-04-01 2023-06-30 0001103090 rscf:OEMAndOtherMember rscf:InternationalMember 2023-04-01 2023-06-30 0001103090 rscf:OEMAndOtherMember 2023-04-01 2023-06-30 0001103090 country:US 2023-04-01 2023-06-30 0001103090 rscf:InternationalMember 2023-04-01 2023-06-30 0001103090 rscf:FreezersAndChillersMember country:US 2024-01-01 2024-06-30 0001103090 rscf:FreezersAndChillersMember rscf:InternationalMember 2024-01-01 2024-06-30 0001103090 rscf:FreezersAndChillersMember 2024-01-01 2024-06-30 0001103090 rscf:OEMAndOtherMember country:US 2024-01-01 2024-06-30 0001103090 rscf:OEMAndOtherMember rscf:InternationalMember 2024-01-01 2024-06-30 0001103090 rscf:OEMAndOtherMember 2024-01-01 2024-06-30 0001103090 country:US 2024-01-01 2024-06-30 0001103090 rscf:InternationalMember 2024-01-01 2024-06-30 0001103090 rscf:FreezersAndChillersMember country:US 2023-01-01 2023-06-30 0001103090 rscf:FreezersAndChillersMember rscf:InternationalMember 2023-01-01 2023-06-30 0001103090 rscf:FreezersAndChillersMember 2023-01-01 2023-06-30 0001103090 rscf:OEMAndOtherMember country:US 2023-01-01 2023-06-30 0001103090 rscf:OEMAndOtherMember rscf:InternationalMember 2023-01-01 2023-06-30 0001103090 rscf:OEMAndOtherMember 2023-01-01 2023-06-30 0001103090 country:US 2023-01-01 2023-06-30 0001103090 rscf:InternationalMember 2023-01-01 2023-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Exhibit 31.1

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Kim Boyce certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Reflect Scientific, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

 

4. The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

 

5. The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions);

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

Dated: August 13, 2024 Signature: /s/ Kim Boyce
  Kim Boyce
  Chief Executive Officer and Director

 

Exhibit 31.2

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Kim Boyce, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Reflect Scientific, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

 

4. The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

 

5. The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions);

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

Dated: August 13, 2024 Signature: /s/ Kim Boyce
  Kim Boyce
  Principal Financial Officer and CFO

 

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

 

In connection with the Quarterly Report of Reflect Scientific, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), We, Kim Boyce, our Chief Executive Officer and director and Kim Boyce, our Chief/Principal Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Dated: August 13, 2024 Signature: /s/ Kim Boyce
  Kim Boyce
  Chief Executive Officer and Director

 

Dated: August 13, 2024 Signature: /s/ Kim Boyce
  Kim Boyce
  Principal Financial Officer and CFO

 

 

 

v3.24.2.u1
Cover - shares
6 Months Ended
Jun. 30, 2024
Aug. 12, 2024
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Entity Interactive Data Current Yes  
Amendment Flag false  
Document Period End Date Jun. 30, 2024  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q2  
Entity Information [Line Items]    
Entity Registrant Name REFLECT SCIENTIFIC, INC.  
Entity Central Index Key 0001103090  
Entity File Number 000-31377  
Entity Tax Identification Number 87-0642556  
Entity Incorporation, State or Country Code UT  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Contact Personnel [Line Items]    
Entity Address, Address Line One 1266 South 1380 West  
Entity Address, City or Town Orem  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84058  
Entity Phone Fax Numbers [Line Items]    
City Area Code (801)  
Local Phone Number 226-4100  
Entity Listings [Line Items]    
Entity Common Stock, Shares Outstanding   85,664,086
v3.24.2.u1
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Current Assets    
Cash and cash equivalents $ 1,102,696 $ 1,277,951
Accounts receivable, net 110,592 108,191
Inventories, net 835,667 972,293
Prepaid expenses and other current assets 14,550 11,715
Total Current Assets 2,063,505 2,370,150
Operating lease right-of-use assets 200,026 235,653
Goodwill 60,000 60,000
Other long-term assets 3,100 3,100
TOTAL ASSETS 2,326,631 2,668,903
Current Liabilities    
Accounts payable and accrued expenses 52,904 86,241
Customer deposits 90,369 447,444
Current portion of operating lease liabilities 72,802 62,681
Total Current Liabilities 216,075 596,366
Operating lease liabilities, net of current portion 140,966 179,963
TOTAL LIABILITIES 357,041 776,329
Stockholders' Equity    
Preferred Stock, $0.01 par value, 5,000,000 shares authorized; none issued and outstanding as of June 30, 2024 and December 31, 2023
Common stock, $0.01 par value, 100,000,000 shares authorized; 85,664,086 shares issued and outstanding as of June 30, 2024 and December 31, 2023 856,640 856,640
Additional paid-in capital 20,302,681 20,302,681
Accumulated deficit (19,189,731) (19,266,747)
TOTAL STOCKHOLDERS’ EQUITY 1,969,590 1,892,574
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 2,326,631 $ 2,668,903
v3.24.2.u1
Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares
Jun. 30, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value (in Dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 85,664,086 85,664,086
Common stock, shares outstanding 85,664,086 85,664,086
v3.24.2.u1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]        
Revenues $ 590,071 $ 124,384 $ 1,018,826 $ 365,511
Cost of goods sold 231,514 63,850 418,480 177,483
Gross profit 358,557 60,534 600,346 188,028
Operating Expenses        
Salaries and wages 148,054 154,569 290,668 316,844
General and administrative 107,555 81,361 239,859 188,353
Research and development 4,605 5,380 11,980 11,446
Total Operating Expenses 260,214 241,310 542,507 516,643
INCOME (LOSS) FROM OPERATIONS 98,343 (180,776) 57,839 (328,615)
INTEREST INCOME 10,644 (312) 19,177 (312)
NET INCOME (LOSS) BEFORE INCOME TAXES 98,343 (180,776) 57,839 (328,615)
INCOME TAX EXPENSE
NET INCOME (LOSS) $ 108,987 $ (181,088) $ 77,016 $ (328,927)
Income (loss) per common share        
Income (loss) per common share - basic (in Dollars per share) $ 0 $ 0 $ 0 $ 0
Weighted average shares outstanding        
Weighted average shares outstanding - basic (in Shares) 85,664,086 85,214,086 85,664,086 85,214,086
v3.24.2.u1
Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Income Statement [Abstract]        
Income (loss) per common share - diluted $ 0.00 $ 0.00 $ 0.00 $ 0.00
Weighted average shares outstanding - diluted 85,664,086 85,214,086 85,664,086 85,214,086
v3.24.2.u1
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
Common Shares
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2022 $ 852,140 $ 20,252,181 $ (18,807,719) $ 2,296,602
Balance (in Shares) at Dec. 31, 2022 85,214,086      
Stock-based compensation 6,875 6,875
Net Income (loss) (147,839) (147,839)
Balance at Mar. 31, 2023 $ 852,140 20,259,056 (18,955,558) 2,155,638
Balance (in Shares) at Mar. 31, 2023 85,214,086      
Balance at Dec. 31, 2022 $ 852,140 20,252,181 (18,807,719) 2,296,602
Balance (in Shares) at Dec. 31, 2022 85,214,086      
Net Income (loss)       (328,927)
Balance at Jun. 30, 2023 $ 852,140 20,265,931 (19,136,646) 1,981,425
Balance (in Shares) at Jun. 30, 2023 85,214,086      
Balance at Mar. 31, 2023 $ 852,140 20,259,056 (18,955,558) 2,155,638
Balance (in Shares) at Mar. 31, 2023 85,214,086      
Stock-based compensation 6,875 6,875
Net Income (loss) (181,088) (181,088)
Balance at Jun. 30, 2023 $ 852,140 20,265,931 (19,136,646) 1,981,425
Balance (in Shares) at Jun. 30, 2023 85,214,086      
Balance at Dec. 31, 2023 $ 856,640 20,302,681 (19,266,747) 1,892,574
Balance (in Shares) at Dec. 31, 2023 85,664,086      
Net Income (loss) (31,971) (31,971)
Balance at Mar. 31, 2024 $ 856,640 20,302,681 (19,298,718) 1,860,603
Balance (in Shares) at Mar. 31, 2024 85,664,086      
Balance at Dec. 31, 2023 $ 856,640 20,302,681 (19,266,747) 1,892,574
Balance (in Shares) at Dec. 31, 2023 85,664,086      
Net Income (loss)       77,016
Balance at Jun. 30, 2024 $ 856,640 20,302,681 (19,189,731) 1,969,590
Balance (in Shares) at Jun. 30, 2024 85,664,086      
Balance at Mar. 31, 2024 $ 856,640 20,302,681 (19,298,718) 1,860,603
Balance (in Shares) at Mar. 31, 2024 85,664,086      
Net Income (loss) 108,987 108,987
Balance at Jun. 30, 2024 $ 856,640 $ 20,302,681 $ (19,189,731) $ 1,969,590
Balance (in Shares) at Jun. 30, 2024 85,664,086      
v3.24.2.u1
Condensed Consolidated Statements of Cash Flows - USD ($)
6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES    
Net income (loss) $ 77,016 $ (328,927)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation   13,750
Amortization of right-of-use assets 35,627 29,257
Changes in operating assets and liabilities:    
Accounts receivable (2,401) 36,612
Inventories 136,626 (79,734)
Prepaid expenses and other current assets (2,835) (3,703)
Accounts payable and accrued expenses (33,338) (35,398)
Customer deposits (357,075) 425,607
Operating lease liabilities (28,876) (30,633)
Net cash (used in) provided by operating activities (175,255) 26,831
CASH FLOWS FROM INVESTING ACTIVITIES    
Net cash provided by investing activities
CASH FLOWS FROM FINANCING ACTIVITIES    
Net cash provided by financing activities
NET CHANGE IN CASH AND CASH EQUIVALENTS (175,255) 26,831
CASH AND CASH EQUIVALENTS    
Beginning of the period 1,277,951 1,381,927
End of the period 1,102,696 1,408,758
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION    
Cash paid for interest
Cash paid for income taxes
v3.24.2.u1
Basis of Presentation and Other Information
6 Months Ended
Jun. 30, 2024
Basis of Presentation and Other Information [Abstract]  
BASIS OF PRESENTATION AND OTHER INFORMATION

NOTE 1—BASIS OF PRESENTATION AND OTHER INFORMATION

 

The accompanying unaudited condensed consolidated financial statements of Reflect Scientific, Inc. (the “Company,” “we,” “us,” or “our”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q of Regulation S-X. They do not include all the information and footnotes required by GAAP for complete financial statements. The December 31, 2023 consolidated balance sheet data was derived from audited financial statements but do not include all disclosures required by GAAP. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 29, 2024. The interim unaudited condensed consolidated financial statements should be read in conjunction with those consolidated financial statements included in the Form 10-K. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the three and six months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.

 

Recently Issued Accounting Pronouncements

 

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about reportable segment’s profit or loss and assets that are currently required annually. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. These amendments are to be applied retrospectively. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements.

 

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which enhances the transparency and decision usefulness of income tax disclosures by requiring; (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. These amendments are to be applied prospectively, with retrospective application permitted. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements.

 

The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to our condensed consolidated financial statements.

v3.24.2.u1
Disaggregation of Revenues
6 Months Ended
Jun. 30, 2024
Disaggregation of Revenues [Abstract]  
DISAGGREGATION OF REVENUES

NOTE 2—DISAGGREGATION OF REVENUES

 

Our revenue is disaggregated based on product category and geographical region. We recognize revenue from the sale of scientific equipment for the life sciences and manufacturing industries. Our products include non-mechanical Cyrometrix freezers, chillers, and original equipment manufacturer (“OEM”) value-added products and components for the life sciences industry.

 

The Company’s revenues for the three months ended June 30, 2024 and 2023 are disaggregated as follows:

 

    For the Three Months Ended June 30, 2024  
    United States     International     Total  
Revenues                        
     Freezers and chillers   $ 391,198     $ -     $ 391,198  
     OEM and other     159,385       39,488       198,873  
Total Revenues $ 550,583     $ 39,488     $ 590,071  

 

    For the Three Months Ended June 30, 2023  
    United States     International     Total  
Revenues                        
    Freezers and chillers   $ 10,508     $ -     $ 10,508  
    OEM and other     81,155       32,721       113,876  
Total Revenues   $ 91,663     $ 32,721     $ 124,384  

 

The Company’s revenues for the six months ended June 30, 2024 and 2023 are disaggregated as follows:

 

    Six Months Ended June 30, 2024
    United States     International     Total  
    Revenues                  
    Freezers and chillers   $ 655,468     $ -     $ 655,468  
    OEM and other     297,181       66,177       363,358  
   Total Revenues   $ 952,649     $ 66,177     $ 1,018,826  

 

    Six Months Ended June 30, 2023
    United States     International     Total  
    Revenues                  
    Freezers and chillers   $ 55,758     $ -     $ 55,758  
    OEM and other     209,035       100,718       309,753  
    Total Revenues   $ 264,793     $ 100,718     $ 365,511  
v3.24.2.u1
Inventories
6 Months Ended
Jun. 30, 2024
Inventories [Abstract]  
INVENTORIES

NOTE 3—INVENTORIES

 

Inventories at June 30, 2024 and December 31, 2023 consisted of the following:

 

    June 30,     December 31,  
    2024     2023  
Finished goods   $ 184,808     $ 493,565  
Raw materials     756,903       584,772  
Total inventories     941,711       1,078,337  
Less reserve for obsolescence     (106,044 )     (106,044 )
Total inventories, net   $ 835,667     $ 972,293  

 

Inventory balances are composed of finished goods and raw materials. Work in process inventory is immaterial to the condensed consolidated financial statements.

v3.24.2.u1
Leases
6 Months Ended
Jun. 30, 2024
Leases [Abstract]  
LEASES

NOTE 4—LEASES

 

The following was included in our condensed consolidated balance sheets at June 30, 2024 and December 31, 2023:

 

    June 30,   December 31,  
    2024   2023  
Operating lease right-of-use assets   $ 200,026   $ 235,653  
               
Lease liabilities, current portion     72,802     62,681  
Lease liabilities, long-term     140,966     179,963  
Total operating lease liabilities   $ 213,768   $ 242,644  
               
Weighted-average remaining lease term (months)     29     35  
Weighted average discount rate     10.5 %   10.5 %

 

Total lease expense for the three and six months ended June 30, 2024 and 2023 is as follows:

 

   

Three Months Ended

June 30,

   

Six Months Ended

June 30,

 
    2024     2023     2024     2023  
Operating lease expense   $ 23,875     $ 15,216     $ 47,750     $ 30,432  
Variable lease expense     -       7,202       -       11,639  
Total lease expense   $ 23,875     $ 22,418     $ 47,750     $ 42,071  

 

Cash payments included in the measurement of our operating lease liabilities were $20,777 and $15,977 for the three months ended and $41,002 and $31,808 for the six months ended June 30, 2024 and 2023, respectively.

 

As of June 30, 2024, maturities of operating lease liabilities were as follows:

  

Year Ending December 31,   Amount  
2024   $ 44,307  
2025     98,532  
2026     101,708  
Total     244,547  
Less: imputed interest     (30,779 )
Total operating lease liabilities   $ 213,768  
v3.24.2.u1
Stockholders' Equity
6 Months Ended
Jun. 30, 2024
Stockholders' Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 5—STOCKHOLDERS’ EQUITY

 

Common Stock

 

As of June 30, 2024 and December 31, 2023, the Company was authorized to issue 100,000,000 common shares, of which 85,664,086 common shares were issued and outstanding.

v3.24.2.u1
Pay vs Performance Disclosure - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Pay vs Performance Disclosure            
Net Income (Loss) $ 108,987 $ (31,971) $ (181,088) $ (147,839) $ 77,016 $ (328,927)
v3.24.2.u1
Insider Trading Arrangements
3 Months Ended
Jun. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Rule 10b5-1 Arrangement Modified false
Non-Rule 10b5-1 Arrangement Modified false
v3.24.2.u1
Accounting Policies, by Policy (Policies)
6 Months Ended
Jun. 30, 2024
Accounting Policies [Abstract]  
Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about reportable segment’s profit or loss and assets that are currently required annually. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. These amendments are to be applied retrospectively. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which enhances the transparency and decision usefulness of income tax disclosures by requiring; (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2025, with early adoption permitted. These amendments are to be applied prospectively, with retrospective application permitted. The Company is currently evaluating the impact this standard will have on its condensed consolidated financial statements.

The Company currently believes there are no other issued and not yet effective accounting standards that are materially relevant to our condensed consolidated financial statements.

v3.24.2.u1
Disaggregation of Revenues (Tables)
6 Months Ended
Jun. 30, 2024
Disaggregation of Revenues [Abstract]  
Schedule of Disaggregated Revenues The Company’s revenues for the three months ended June 30, 2024 and 2023 are disaggregated as follows:
    For the Three Months Ended June 30, 2024  
    United States     International     Total  
Revenues                        
     Freezers and chillers   $ 391,198     $ -     $ 391,198  
     OEM and other     159,385       39,488       198,873  
Total Revenues $ 550,583     $ 39,488     $ 590,071  
    For the Three Months Ended June 30, 2023  
    United States     International     Total  
Revenues                        
    Freezers and chillers   $ 10,508     $ -     $ 10,508  
    OEM and other     81,155       32,721       113,876  
Total Revenues   $ 91,663     $ 32,721     $ 124,384  
    Six Months Ended June 30, 2024
    United States     International     Total  
    Revenues                  
    Freezers and chillers   $ 655,468     $ -     $ 655,468  
    OEM and other     297,181       66,177       363,358  
   Total Revenues   $ 952,649     $ 66,177     $ 1,018,826  
    Six Months Ended June 30, 2023
    United States     International     Total  
    Revenues                  
    Freezers and chillers   $ 55,758     $ -     $ 55,758  
    OEM and other     209,035       100,718       309,753  
    Total Revenues   $ 264,793     $ 100,718     $ 365,511  
v3.24.2.u1
Inventories (Tables)
6 Months Ended
Jun. 30, 2024
Inventories [Abstract]  
Schedule of Inventories Inventories at June 30, 2024 and December 31, 2023 consisted of the following:
    June 30,     December 31,  
    2024     2023  
Finished goods   $ 184,808     $ 493,565  
Raw materials     756,903       584,772  
Total inventories     941,711       1,078,337  
Less reserve for obsolescence     (106,044 )     (106,044 )
Total inventories, net   $ 835,667     $ 972,293  
v3.24.2.u1
Leases (Tables)
6 Months Ended
Jun. 30, 2024
Leases [Abstract]  
Schedule of Consolidated Balance Sheet The following was included in our condensed consolidated balance sheets at June 30, 2024 and December 31, 2023:
    June 30,   December 31,  
    2024   2023  
Operating lease right-of-use assets   $ 200,026   $ 235,653  
               
Lease liabilities, current portion     72,802     62,681  
Lease liabilities, long-term     140,966     179,963  
Total operating lease liabilities   $ 213,768   $ 242,644  
               
Weighted-average remaining lease term (months)     29     35  
Weighted average discount rate     10.5 %   10.5 %
Schedule of Lease Expense Total lease expense for the three and six months ended June 30, 2024 and 2023 is as follows:
   

Three Months Ended

June 30,

   

Six Months Ended

June 30,

 
    2024     2023     2024     2023  
Operating lease expense   $ 23,875     $ 15,216     $ 47,750     $ 30,432  
Variable lease expense     -       7,202       -       11,639  
Total lease expense   $ 23,875     $ 22,418     $ 47,750     $ 42,071  
Schedule of Maturities of Operating Lease Liabilities As of June 30, 2024, maturities of operating lease liabilities were as follows:
Year Ending December 31,   Amount  
2024   $ 44,307  
2025     98,532  
2026     101,708  
Total     244,547  
Less: imputed interest     (30,779 )
Total operating lease liabilities   $ 213,768  
v3.24.2.u1
Disaggregation of Revenues (Details) - Schedule of Disaggregated Revenues - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenues        
Total Revenues $ 590,071 $ 124,384 $ 1,018,826 $ 365,511
United States [Member]        
Revenues        
Total Revenues 550,583 91,663 952,649 264,793
International [Member]        
Revenues        
Total Revenues 39,488 32,721 66,177 100,718
Freezers and Chillers [Member]        
Revenues        
Total Revenues 391,198 10,508 655,468 55,758
Freezers and Chillers [Member] | United States [Member]        
Revenues        
Total Revenues 391,198 10,508 655,468 55,758
Freezers and Chillers [Member] | International [Member]        
Revenues        
Total Revenues
OEM and Other [Member]        
Revenues        
Total Revenues 198,873 113,876 363,358 309,753
OEM and Other [Member] | United States [Member]        
Revenues        
Total Revenues 159,385 81,155 297,181 209,035
OEM and Other [Member] | International [Member]        
Revenues        
Total Revenues $ 39,488 $ 32,721 $ 66,177 $ 100,718
v3.24.2.u1
Inventories (Details) - Schedule of Inventories - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Schedule of Inventories [Abstract]    
Finished goods $ 184,808 $ 493,565
Raw materials 756,903 584,772
Total inventories 941,711 1,078,337
Less reserve for obsolescence (106,044) (106,044)
Total inventories, net $ 835,667 $ 972,293
v3.24.2.u1
Leases (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Leases [Abstract]        
Operating lease $ 20,777 $ 15,977 $ 41,002 $ 31,808
v3.24.2.u1
Leases (Details) - Schedule of Condensed Consolidated Balance Sheet - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Schedule of Consolidated Balance Sheet [Abstract]    
Operating lease right-of-use assets $ 200,026 $ 235,653
Lease liabilities, current portion 72,802 62,681
Lease liabilities, long-term 140,966 179,963
Total operating lease liabilities $ 213,768 $ 242,644
Weighted-average remaining lease term (months) 29 months 35 months
Weighted average discount rate 10.50% 10.50%
v3.24.2.u1
Leases (Details) - Schedule of Lease Expense - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Schedule of Lease Expense [Abstract]        
Operating lease expense $ 23,875 $ 15,216 $ 47,750 $ 30,432
Variable lease expense 7,202 11,639
Total lease expense $ 23,875 $ 22,418 $ 47,750 $ 42,071
v3.24.2.u1
Leases (Details) - Schedule of Maturities of Operating Lease Liabilities - USD ($)
Jun. 30, 2024
Dec. 31, 2023
Schedule of Maturities of Operating Lease Liabilities [Abstract]    
2024 $ 44,307  
2025 98,532  
2026 101,708  
Total 244,547  
Less: imputed interest (30,779)  
Total operating lease liabilities $ 213,768 $ 242,644
v3.24.2.u1
Stockholders' Equity (Details) - shares
Jun. 30, 2024
Dec. 31, 2023
Stockholders' Equity [Line Items]    
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 85,664,086 85,664,086
Common stock, shares outstanding 85,664,086 85,664,086

Reflect Scientific (QB) (USOTC:RSCF)
Historical Stock Chart
From Sep 2024 to Oct 2024 Click Here for more Reflect Scientific (QB) Charts.
Reflect Scientific (QB) (USOTC:RSCF)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more Reflect Scientific (QB) Charts.